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“I am accordingly of the opinion that the normal regulation
of islet content in the pancreas is by interstitial growth of
pre-existing islets and by the formation of new islets from
the duct epithelium, and not at all by the formation of new
islets out of acini.”
R.R. Bensley
Am J Anatomy 1911;12:297–388
F
or almost a century (for historical review, see 1)
both -cell replication and neogenesis (the dif-
ferentiation of new islet cells from progenitors or
stem cells) have been thought to be responsible
for postnatal growth of the endocrine pancreas. Even
though doubts have been raised in recent years about the
existence and importance of neogenesis, this skepticism
may be subsiding. Replication and neogenesis are not
mutually exclusive. Both processes often occur simulta-
neously, as seen during the regeneration that follows
pancreatic injury. However, there are important differ-
ences in the balance of these two pathways that depend
upon species and age. Replication of -cells is an impor-
tant mechanism particularly in adult rodents, but there are
compelling data that after-birth progenitors also have a
role in renewal and growth of islets. Eventually one or
both of these pathways may be manipulated for therapeu-
tic treatment of diabetes. Since we and others have
extensively reviewed the regulation of -cell mass (2,3),
this Perspective will speciﬁcally address the contributions
of the neogeneic pathway to new -cell formation, consid-
ering whether postnatal neogenesis occurs, to what ex-
tent; possible differences between mammalian species;
and whether it might be exploited therapeutically.
-Cell expansion in normal growth. The concept that
-cell mass is dynamic and increases and decreases both
in function and mass to maintain the glycemic level within
a very narrow physiological range (4) is now generally
accepted. In both normal and pathophysiological states,
the mechanisms responsible are changes in replication
and neogenesis, changes in individual cell volume, and
changes in cell loss or death rates. In rodents, -cell
replication is signiﬁcantly higher during late gestation and
the neonatal period than after weaning and changes little
beyond 30–40 days of age except in response to physio-
logical/pathological changes (2,3,5). Other than during the
neonatal remodeling of the endocrine pancreas that oc-
curs before weaning (6), the frequency of apoptosis is low
and unchanging (7). In the initial months of life, -cell
mass increases with body weight through increases in
both -cell number and size, but in old (15–20 months) rats
the increment in mass is largely accounted for by in-
creased -cell size (7). While replication and apoptosis of
the -cell have been the focus of many studies in the last
decade, changes in cell volume are usually not measured;
however, changes have been well documented in a num-
ber of other models (8–10). In the case of neogenesis,
there is strong evidence that the process occurs normally
and can be activated in mouse, rat, pig, and human.
The concept of neogenesis or the formation of new islet
cells from pancreatic progenitor/stem cells after birth has
been built upon many observations from different models
and species over many years. An appealing assumption
has been that the islet hormone-positive cells within the
ductal epithelium or that appear to be “budding” from the
ducts represent neogenesis (Figs. 1 and 2). However, it can
be argued that they are static with no active “budding” or
neogenesis (11). Other than lineage tracing, no direct
means of showing a dynamic process of neogenesis exists,
but with the limited labeling efﬁciency of current lineage-
tracing approaches, detection of marked cells rather than
the lack of such cells represents stronger evidence. Many
studies have quantiﬁed neogenesis as increased hormone-
positive cells within ducts or small clusters of hormone-
positive cells in the parenchyma that accompany growth
whether normal growth, after surgical perturbation or
addition of various growth factors and/or cytokines. These
data have strengthened the hypothesis that this budding
appearance actually represents the dynamic process of
neogenesis, such that hormone-positive cells within ducts
may be used as quantiﬁable markers. Table 1 shows more
quantitative studies over the past several decades; more
detail is provided below about some of these models. It
should be noted that not all rodent models of -cell growth
show neogenesis: no increases in islet number were seen
in pregnancy in mice (12) or in adult ob/ob mice compared
with ob/ controls (13); both of these studies showed
increased -cell mass with larger islets, supporting repli-
cation as the mechanism of expansion. One must be aware
of possible species differences, as illustrated by neogene-
sis not being reported in adult mice fed a high-fat diet but
reported in adult pigs that became obese after ad libitum
feeding for 1–2 years (14). Additionally, in contrast to the
data from rodents, the adaptive increase in -cells during
pregnancy in humans is accompanied by decreased mean
islet size, increased number of -cells in “apparently new
small islets” with no change in -cell size, replication, or
apoptosis frequency (15).
However, largely based on Dor et al. in 2004 (11), the
occurrence of neogenesis has been questioned (16,17).
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rat insulin promoter:CreER mice was not diluted over
several months of chase in adult mice, showed that
replication as a major mechanism of -cell expansion in
adult mice. However, with possible low levels of leakiness
of the Cre-lox system over time with the strong insulin
promoter (18), the small proportion of the islets counted,
and only 30% labeling of the -cells, neogenesis in the
adult cannot be ruled out by negative data of a lack of
dilution of labeled -cells. Furthermore, the common
extrapolation of these data that neogenesis does not occur
after birth is ﬂawed since neither the neonatal period nor
the new lobes after pancreatectomy were examined.
In building a case for a given hypothesis, it has become
fashionable to rely more heavily upon genetic methodol-
ogy than correlative observations. However, each ap-
proach has its strengths and limitations. In the case of
neogenesis, years of strong observational support had now
been supplemented by molecular tracing experiments,
with two strong studies (19,20) in 2008 that complement
past evidence for postnatal neogenesis.
Neogenesis in normal growth during the neonatal
period. During the fetal stage, differentiation is the major
mechanism for forming new -cells, but replication or
self-duplication is enhanced during the perinatal period.
During the neonatal period, -cell replication continues
and signiﬁcant neogenesis occurs under these normal
physiological conditions, as has been demonstrated using
various methods, including Cre-lox lineage tracing
experiments.
Bouwens et al. (21) studying neonatal rat pancreas in
the ﬁrst 2 weeks after birth suggested that cytokeratin 20
(a marker of rat duct epithelium) cells at the periphery of
islets served as islet progenitors. Between 2 and 5 days of
age, the -cell mass more than doubled, but the cross-
sectional area of the -cells was unchanged, indicating
that new cells rather than larger cells accounted for the
increased mass. The BrdU incorporation in -cells of 2.4%
at day 2 could account for only 12% of the observed growth
by day 5. It was concluded that most of the new -cells
originated from neogenesis. Their observation that CK20
cells had higher BrdU incorporation than hormone-posi-
tive cells is consistent with the ﬁnding that duct cell
replication precedes neogenesis (22).
Our mathematical modeling study (5) predicted two
waves of neogenesis: one immediately after birth and the
other 2–3 weeks after birth. This model used existing data
on -cell mass and its determinants (cell volume, replica-
tion, and apoptosis frequency) to estimate turnover of
-cells. In our subsequent longitudinal study of -cell mass
and its determinants over the ﬁrst month after birth (6), we
documented the increased appearance of islets budding
from the ducts at the same times (shortly after birth and
just before weaning), conﬁrming the predicted waves of
neogenesis. Using these data to estimate the number of
-cells at each time point, we estimated that 70% of the
-cells seen at day 31 could be accounted for by replica-
tion of preexisting -cells, while the remaining 30% were
from neogenesis (22). This estimate is consistent with the
E-cadherin
Insulin
A Insulin
Amylase
B
FIG. 1. Neogenesis in mouse pancreas. A: The metaplastic ducts seen in the zinc-treated metallothionen. TGF- transgenic mice have 6% insulin
(red, white arrows) cells and some amylase (green, yellow arrow) cells. Tissue from study reported in (37); the background in the red channel
was enhanced to see the context of the ducts. Magniﬁcation bar  100 m. B: After partial (70–80%) pancreatectomy in adult mice, insulin
(blue) cells “budding” from proliferating ductules labeled with E-cadherin (red) are found in well-deﬁned areas termed foci of regeneration that
further differentiate into new lobes of pancreas (40). Magniﬁcation bar  50 m. (A high-quality digital representation of this ﬁgure is available
in the online issue.)
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ments described next (20).
Carbonic anhydrase II (CAII), which only starts to be
expressed in ducts at the very end of gestation (23), has
been considered a marker for ducts to distinguish the
mature ductal phenotype from the embryonic tubular
structures often called embryonic ducts. Thus, bigenic
CAIICre:ROSA26R mice can provide duct-speciﬁc lineage
tracing with only genetically marked ducts expressing the
reporter at birth with no CAII or Cre expressed in -cells
(20). We showed that in the 4 weeks after birth, both islets
and acini were formed from cells that once expressed
CAII: 38% of the islets were marked (17% of all insulin
cells) as well as a number of acinar cells; some lobes were
marked and others not. Since the pancreatic weight in-
creases fourfold between day 17 and day 31 (6), we
interpret the lobular pattern of marked islets and acini as
evidence of new lobe formation in the neonatal period. It
should be noted that two recent lineage-tracing studies
using inducible Cre-ER driven by either the hepatocyte
nuclear factor (Hnf) 1 (24) or mucin1 promoter (25)
found no marked islet nor acinar tissue in neonates when
tamoxifen was administered at the end of gestation (24) or
birth (25). These studies found only marked ducts during
this time of rapid pancreatic expansion, but their negative
data may be due to 1) their low efﬁciency of marking ducts
(20 and 7.6%, respectively) and only 1,000 insulin cells
counted per animal and 2) a marked heterogeneity within
the ducts of the expressed product of their driver gene.
Recently, Peng et al. (26) published studies that showed
an increasing number of islets from 1 week to 2 months of
age. The obvious caveat for enumeration of islets over
time in that small clusters of islet cells, which initially may
have been below the measurable limit, may increase in
size due to proliferation and be counted as newly formed.
Interestingly, they also report that Ki67 mRNA and telo-
mere length were signiﬁcantly correlated in single islets at
either 2 weeks or 4 months but differed for islets within the
same animal, suggesting islets of differing ages in adult
mice.
If new islets were generated from preexisting ductal
tissue, one might expect expression of residual duct
markers for a short period of time after hormone expres-
sion. Indeed, transient expression of markers of duct cells
has been demonstrated in -cells of newborn rats (27) as
well as in regenerated islets after partial pancreatectomy
(22,28), in grafts of puriﬁed human duct cells (29), and in
islets of mice conditionally expressing Pax4 in glucagon-
producing cells (POE::GluCre) (30), suggesting their re-
cent passage through the ductal phenotype.
Models of regeneration associated with neogenesis.
Both partial pancreatectomy (31) and partial duct ligation
(32), classic models of regeneration in rodents, are fol-
lowed by both -cell replication and neogenesis. Adding to
the weight of evidence, newly formed or “budding” islets
have been found in a number of other experimental
conditions (Table 1), including dietary treatment with
soybean trypsin inhibitor (33), after glucagon-like peptide
(GLP)-1/exendin-4 treatment (8), treatment with betacel-
lulin (34), and after cellophane wrapping of the head of the
pancreas (a partial duct obstruction) (35). Additional
strong evidence of formation of new -cells from differen-
tiation of progenitors comes from a number of transgenic
models, including overexpression of interferon- in the
-cells of transgenic mice (36), overexpression of trans-
forming growth factor (TGF)- in pancreatic ducts (37),
and Pax4 ectopic expression in glucagon-positive cells
(30). These regeneration models may not be normal phys-
iology but may show pathways that can be exploited, as
much as transgenic and knockout mice are hardly physi-
ological but quite informative.
A B
FIG. 2. Neogenesis in adult human pancreas. Insulin (brown) cells seen in the ducts in adult human pancreas. A: Surgical sample from patient
who had partial pancreatectomy due to recurrent postprandial hypoglycemia after gastric bypass as reported in Patti et al. (79). While no Ki67
islet cells were seen in sections from this pancreas, many ductal cells were Ki67 (not shown) and many insulin cells are seen within the
ductules. Magniﬁcation bar  100 m. B: Insulin cells are found within the ductal epithelium in human pancreas. Magniﬁcation bar  20 um.
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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ctomy in rats demonstrates the substantial regenerative
capacity of the adult pancreas (31,38,39). By 8 weeks
after surgery, the 10% remnant had regenerated such
that the pancreatic weight was 27% and the -cell mass
was 45% of the sham-operated pancreas. This was
accounted for by both increased -cell proliferation and
formation of whole-new lobes of pancreas that con-
tained newly formed islets (31,40). Expansion of the
ductal tree by replication could be demonstrated with
BrdU incorporation and subsequent appearance of
branching ductules in well-deﬁned areas (foci of regen-
eration) that correspond to new lobes. The pancreatic
duct cells after replication transiently express pancre-
atic duodenal homeobox (PDX)-1 protein (41) and lose
expression of key markers of the mature duct pheno-
type (40). The appearance of these focal regions and
their disappearance with maturation coincide with the
marked growth of the pancreatic remnant. Within a
single pancreas, there are multiple focal areas of varying
stages of maturation, as assessed by their histological
appearance and gene expression proﬁles. Ductules in
these foci express many markers of embryonic pancre-
atic progenitors, including transient expression of the
TABLE 1
Studies providing evidence of in vivo neogenesis
Species Observation References
Rat
Neonates Islet mass growth from cytokeratin cells at periphery
of islets; -cell mass determinants measured, and
mathematical modeling
Bouwens et al. (21); Wang
et al. (89); Finegood et al.
(5); Scaglia et al. (6);
Bonner-Weir et al. (22)
Neonatal STZ Appearance of small islet clusters associated with ducts Portha and colleagues (90)
Duct ligation Appearance of small islet clusters associated with ducts Edstrom (50)
Wang et al. (32)
Duct ligation  gastrin Appearance of small islet clusters associated with ducts Rooman et al. (52)
Pancreatectomy (90%) New lobe formation with new islets, enhanced
replication too
Bonner-Weir and colleagues
(31, 38)
Zucker fatty and Zucker fatty diabetic Increased small islet clusters associated with ducts Pick et al. (91)
Zucker fatty rats Increased small islets associated with ducts, increased
number islets
Jetton et al. (44)
20% glucose infusion (48 h) Increased small islet clusters associated with ducts Jetton et al. (92)
Exendin 4 Increased hormone cells in ducts Xu et al. (8)
Soybean trypsin inhibitor Increased volume of insulin cells in ducts Weaver et al. (33)
Mouse
Early postnatal Increased number of islets from 1 week to 2 months;
lineage tracing of duct-speciﬁc promoter birth to 4
weeks
Inada et al. (20);
Peng et al. (26)
Ductal ligation Ngn3 cells in and adjacent to ducts Xu et al. (19)
CAIICreERT lineage tracing Inada et al. (20)
Alloxan perfusion to part of pancreas Replication in nonperfused part and neogenesis in
perfused
Waguri et al. (34)
Alloxan  betacellulin Increased ICC/mm
2 pancreas Yamamoto et al. (93)
Alloxan  adv-betacellulin Signiﬁcantly increased insulin duct cells Tokui et al. (94)
Alloxan  EGF and gastrin Signiﬁcantly increased insulin duct cells Rooman and Bouwens (95)
Pancreatectomy (60%) Increased small clusters before -cell proliferation;
FOXM1 necessary for proliferation but for not
neogenesis
Peshavaria et al. (46);
Ackermann Misfeldt
et al. (47)
Retroductal adv-GFP (neonatal) GFP in islets over ﬁrst 2 weeks Peng et al. (26)
Metallothionen:TGF-Ins:gastrin Insulin cells in metaplastic ducts, increased islets Wang et al. (37)
RIP:interferon- Increased insulin clusters in ducts Gu and Sarvetnick (36)
NeuroD-null mice 10% duct in null mice had “budding” insulin cells Huang et al. (96)
Glucagon:Pax4 Reprogramming of -t o-cells and replenishment of 
from ducts
Collombat et al. (30)
Pig
Obese minipig, after 1 of year age Increased islet numbers but same mean volume of islets Larsen et al. (14)
Human
Autopsied pancreas, birth to age 20
years
After 12 years, most 0.5–1.2% insulin duct cells, some
none
Meier et al. (62)
Donor pancreas, aged 7–70 years Unchanged low level of neogenesis from 7 to 70 years Reers et al. (65)
Autopsied, control subjects Obese 1.2% insulin duct cells but lean 0.6  0.2%
insulin duct cells
Meier and colleagues
(66, 74)
Autopsied, chronic pancreatitis Signiﬁcantly increased glucagon or insulin duct cells Phillips et al. (76)
Biopsied failed pancreatic transplant Increased insulin ducts in transplants with recurrent
autoimmunity
Martin-Pagola et al. (78)
Pregnancy Increased -cells with no change in replication, cell
size, or apoptosis frequency; increased insulin duct
cells and very small islets
Butler et al. (15)
S. BONNER-WEIR AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2343endocrine lineage-speciﬁc transcription factor neuroge-
nin 3 (40). Islets in these foci resemble embryonic islets
with higher proportion of insulin cells lacking MafA
expression; the proportion of MafA/insulin cells
increases as foci differentiate further, but even in ma-
ture foci the proportion of MafA-expressing -cells was
lower than in the remnant pancreas of the same animals
(40). We conclude that in response to pancreatectomy,
pancreatic duct cells recapitulate aspects of embryonic
pancreas differentiation and contribute to the regener-
ating pancreas.
After partial pancreatectomy, regeneration is not limited
to young animals. Both replication and neogenesis could
be demonstrated in retired breeder (500 g) rats subjected
to the same surgery (42). Whole-new lobes of pancreas
may even be formed spontaneously in normal adult ani-
mals; occasional pancreatic lobes with high BrdU incor-
poration were seen in 6-month-old rats when most of the
pancreas had almost none (5,22). When the extent of
resection of pancreas is less, there is less regeneration
(43). Even so, Jetton et al. (44) have utilized the 60%
pancreatectomy in adult rats extensively and reported
enhanced -cell proliferation and neogenesis.
The partial pancreatectomy model has been transferred
to mice using less extensive resection, often only 50%. In
several reports, only enhanced replication was reported
(11,16,45), but two groups using 60% pancreatectomy
reported neogenesis in addition to enhanced replication
(46,47). These latter studies have even deﬁned some of the
regulatory pathways involved in neogenesis. Using 70–
80% pancreatectomy in C57BL/6 mice, we obtain mild to
moderate hyperglycemia and have found the same regen-
eration pattern as in 90% pancreatectomy rats (Fig. 1B)
(48).
Partial duct ligation in rodents. The partial duct liga-
tion has been used for several decades in rats (32,49–52).
Wang et al. (32) did a comprehensive study of this model
and showed that the -cell population distal to the ligation
doubled in 1 week and that the labeling index with BrdU
pulse labeling in -cells could not account for this in-
crease. With increased number of small islets and islet cell
clusters in the distal ligated portion, they concluded that
there was islet neogenesis. A value of this model is that
regeneration is limited to the portion distal to the ligation,
allowing an internal control. In later experiments, this
model was used to show that gastrin would stimulate
-cell neogenesis in the distal portion but not in the
pancreas proximal to the ligation (52).
Importantly, this model transferred to mice has been
useful in lineage-tracing studies. For example, with duct
ligation on acinar-speciﬁc elastase 1 promoter:ROSA 26R
bigenic mice, Desai et al. (53) found no marked islets after
ductal ligation and concluded that acinar cells did not
contribute to in vivo new islet formation after pancreatic
ligation. Then, in a series of elegant experiments with
various neurogenin 3 reporter mice, Heimberg and col-
leagues (19) showed that neurogenin 3 was induced in
cells in or adjacent to the pancreatic ducts after partial
duct ligation. By isolating these cells with ﬂow cytometry
and subsequent transplanting them into explants of em-
bryonic pancreas from neurogenin 3–null mice, they
showed that these cells gave rise to islet cells including
-cells. While lineage tracing was not performed, these
data provide strong support for the concept that multipo-
tent progenitor cells can be activated to increase the islet
mass. Complementing these experiments, we tested the
hypothesis that duct cells could give rise to -cells by
doing partial duct ligation in inducible duct-speciﬁc car-
bonic anhydrase II Cre
ERT:Rosa26R bigenic mice (20). In
the distal, regenerated pancreas, 42% of the islets (24%
-cells) were marked compared with 12% (5.5% -cells) in
the nonligated pancreas of the same animals. Thus, these
studies using duct ligation in adult mice have clearly
shown that new islet cells can be formed from progenitors
activated in the ducts.
Transgenic mice overexpressing cytokines/growth
factors/transcription factors. A number of transgenic
mice have reported increased neogenesis, but only three
will be described herein. The most studied transgenic
model of neogenesis is the human insulin promoter, inter-
feron- mouse (54). These mice were found to have
continual inﬂammatory destruction of islets associated
with continued proliferation of ductal epithelium and
“budding” of new islets from the ducts. Originally the
insulitis seen in this model was thought to trigger the
neogenesis, but similar results were found with this trans-
gene in immunocompromised mice. In these proliferating
ducts, the expression of PDX-1 protein and other tran-
scription factors seen in embryonic pancreatic develop-
ment suggested that this regeneration recapitulates the
embryonic process (55,56).
A second transgenic model, the metallothionein-1–
TGF- mouse, also provides evidence of neogenesis from
ducts. The induction of TGF- in the exocrine pancreas by
zinc in the drinking water (57) resulted in sustained
proliferation of the ductal epithelium and metaplastic
ducts. In these metaplastic ducts, 6% of the cells were
immunostained for insulin (37) (Fig. 1A). Moreover, en-
hanced PDX-1 expression and focal expression of Pax6
suggested the initiation of islet neogenesis (58). When
these mice were crossed with mice in which gastrin
expression was driven by the insulin promoter, the num-
ber of metaplastic ducts was reduced and islet mass
increased, leading to the hypothesis that gastrin could
drive the differentiation of progenitors to islets (37).
More recently, another variation of neogenesis of islet
cells from ducts has been shown in bigenic Pax4:glucagon
Cre (POE::gluCre) transgenic mice (30), in which Pax4 is
expressed in glucagon-expressing -cells. This ectopic
expression of Pax4 reprogrammed the -cells to insulin-
producing -cells. However, even with continuing conver-
sion to -cells, there were still -cells, suggesting a
renewal of the -cell population. The authors concluded
that -cell neogenesis occurred since 1) BrdU incorpora-
tion was mainly in cells within or adjacent to the duct
epithelium rather than in hormone-expressing cells; 2)
using a lentiviral reporter injected into the ductal tree, and
both glucagon and insulin-positive cells were labeled in
the induced transgenic mice but not in noninduced con-
trols, suggesting that the hormone reporter cells were
derived from the labeled ducts; and 3) knockdown of
neurogenin 3 with shRNA blocked the replenishment of
the -cells.
-Cell compensation in human pancreas. Our main
interest in studying rodent pancreas is to understand what
happens in the human pancreas with which we cannot do
the same experiments. We know that the pancreatic -cell
mass is increased in human obesity albeit less than in
rodents. Whereas mice can have a 30-fold increase in
-cell mass with insulin resistance or obesity (59), the
estimate for the increase in humans is more like 30–40%
(60,61). Yet, -cell proliferation in adult humans is ex-
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autopsied human pancreas, -cell replication (Ki67
-cells) drops to 	0.2% already by 5 years of age (62) and
can be almost negligible in adults (63,64). However, this
low level of detection may result from the tissue being
only retrieved after death. In a recent study on human
organ donor pancreases, all pancreases had Ki67 -cells,
with a stable, albeit low, percentage in those donors 40–65
years of age (65). An intriguing report documents in-
creased Ki67 -cells (0.69  0.15%) in a surgically
resected pancreas from an 89-year-old with recent-onset
type 1 diabetes (66), suggesting that -cell replication
could still be stimulated.
A major difference between mice and humans is that in
humans telomere shortening limits replication and leads to
senescence, a process described as replicative aging (67).
In contrast, mice have long telomeres and do not show
impairment of replication for several generations after
ablation of telomerase (68,69). Similarly rats do not show
replicative aging (70,71). This difference in replicative
aging could account for the differential response (prolifer-
ation versus differentiation from stem cells/progenitors) in
-cell compensation (72).
Evidence of neogenesis in human pancreas. Due to the
limits of experimentation possible on human pancreas,
our knowledge is based mainly on observations made from
pancreases obtained at autopsy, pancreas donation, and
surgical resection. A number of pathological reports cite
increased hormone-positive cells within the ducts in some
human diseases, such as recent-onset type 1 diabetes and
severe liver disease (73). In a recent study on pancreata
harvested from organ donors (65), insulin cells in pan-
creatic ducts were usually present at low levels (0.4%)
across the age span of 7–70 years. Similarly, in autopsied
pancreata after the age of 12, 0.5–1.2% of the duct cells
were insulin, although in some pancreata none could be
found (62). In other studies by Meier and colleagues
(74,75) in lean controls, 0.6  0.2% of duct cells were
insulin but in pancreata from obese patients, 1.2%. In 10
pancreata from patients with chronic pancreatitis, there
were signiﬁcant increases in the percentage of duct cells
positive for glucagon, amylase, Ki67, Pdx1, or insulin
compared with control pancreata (76). It is of interest that
in a small series of patients with 50% pancreatectomy,
there was no evidence of pancreatic or -cell regeneration
and no change in Ki67 or insulin cells in ducts (77), but
this is not surprising because replication would only be
expected shortly after the surgery. Further evidence that
these hormone-positive cells within the ducts were dy-
namic comes from the comparison of 16 donor pancreata
and biopsied pancreata from eight simultaneous pancreas
and kidney transplantations (78). In the donor pancreata,
the frequency of 0.45% insulin duct cells was similar to
the other above-mentioned studies and in three trans-
plants without autoimmune recurrence (0.5%). However,
in ﬁve pancreatic transplants with recurrent autoimmu-
nity, 57.5% of the duct cells expressed insulin protein. This
unexpectedly high value needs to be conﬁrmed. Still more
evidence suggesting neogenesis in humans comes from a
small group patients who develop hypoglycemia after
gastric bypass surgery (79). They have been found to have
increased -cell mass and impressive numbers of islet
cells within the ducts (Fig. 2A), accompanied by high
circulating levels GLP-1, which has been shown to stimu-
late neogenesis in rodents (8). From these accumulating
circumstantial data, one can be more conﬁdent that neo-
genesis is an important process in humans.
Evidence of neogenesis from human tissue in vitro or
transplanted into mice. With the caveat that tissue in
vitro may be released from a number of regulatory con-
trols and thereby appear more plastic, there is strong
evidence that neogenesis can occur in human pancreatic
tissue. Starting with the islet-depleted pancreatic digest
remaining after islet isolation, several groups were able to
show increased islet cells and increased insulin mRNA
(80–83). Indeed, in our own in vitro studies, collections of
new islet cells could be seen budding from cysts of duct
epithelium (80). Since all of these studies were con-
founded by the possible inclusion of -cells in the starting
material, we puriﬁed human ductal cells, using immuno-
magnetic beads and an antibody against the cell surface
antigen CA19–9, and transplanted aggregates of expanded
duct cells into immunocompromised mice (29). Here, too,
we could show the induction of insulin cells and insulin
mRNA. Some insulin cells in the grafts coexpressed duct
markers (CK19 and CA19-9) and HSP27, a marker of
nonislet cells, suggesting their transition from duct.
Suarez-Pinzon and colleagues (84,85) have provided
further support to activation of neogenesis in human
pancreatic ducts. First, using human pancreatic prepara-
tions that included islets, ducts and acinar cells treated 4
weeks in vitro with the combination of EGF and gastrin
were found to have a doubling of -cells with similar
increases in the number of cells expressing the duct
marker cytokeratin 19 and the transcription factor IPF-1/
PDX-1 (84). Then, in a later study (85), similar low-purity
human islet preparations were dispersed and transplanted
under the kidney capsule of streptozotocin-induced dia-
betic NOD-scid mice, which then were treated with GLP-1
and gastrin for 5 weeks. In those treated with this combi-
nation, there was a fourfold increase in insulin cells
compared with vehicle-treated controls from the same
donor pancreas, with a high proportion of insulin cells
also expressing cytokeratin 19.
What is the cell of origin of the neogeneic islet cells?
A major question about neogenesis under debate is, What
is the cell of origin? Most reports have suggested a cell of
origin in or adjacent to the pancreatic duct epithelium, but
is it a true stem cell, a differentiated duct epithelial cell
capable of multipotent redifferentiation, or some other cell
type? If a duct cell, can any duct cell have the potential or
just a subpopulation? Xu et al. (19) clearly showed neuro-
genin 3 activation in cells within or adjacent to the ducts,
and our report (20) showed that carbonic anhydrase II was
expressed in the cell of origin. However, the recent Solar
et al. (24) study using Hnf1 promoter as a driver for the
Cre recombinase excision did not ﬁnd any marked -cells
after partial duct ligation. Their interpretation was that
differentiated duct cells do not contribute to new -cell
formation but a more precise interpretation would be that
duct cells with high enough levels of Hnf1 transcription
to cause excision do not have this potential (86).
In light of the report of Solar et al. (24), a redeﬁned
question should be, Are there identiﬁable subpopulations
within the ductal tree and which ones have progenitor
potential? We asked whether there is a heterogeneity of
expression of progenitor markers throughout the ductal
tree (87) by immunostaining with titration of antibodies
against Hnf1 and Sox9. Both proteins can be found
throughout the pancreatic ductal tree, but the intensity
and proportion of the expressing population varies within
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express both. Better understanding of this heterogeneity
may deﬁne a progenitor population. The recent identiﬁca-
tion of a population of terminal ductule/centroacinar cells
that express high activity of aldehyde dehydrogenase 1
and have the ability to self-renew and to differentiate into
both endocrine and acinar cells (88) adds new exciting
directions for study. Moreover, expansion of these cells
was found in chronic caerulein-induced pancreatitis. Fur-
ther characterization of this population of cells in various
other models is now a clear priority.
In summary, considering the overall body of evidence,
we can only conclude that both replication of preexisting
-cells and neogenesis are pathways that contribute to
maintaining an adequate -cell mass after birth. Data show
that both pathways are functional in all mammalian spe-
cies studied, but different contributions, which are quan-
titative rather than qualitative, are made in different
species and under different conditions. Eventually, one or
both of these pathways may be manipulated for therapeu-
tic treatment of diabetes. Our next efforts should address
important questions such as, What is the cell of origin?
what are the pathways that drive the activation of the
progenitors? can we selectively stimulate neogenesis and
to what extent? how applicable will these treatments be
for human therapy?
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